Article
Larotinib in patients with advanced and previously treated esophageal squamous cell carcinoma with epidermal growth factor receptor overexpression or amplification: an open-label, multicenter phase 1b study.
BMC gastroenterology - 23 Oct 2021
Liu Rongrui, Liu Lianke, Zhao Chuanhua, Bai Yuxian, Zheng Yulong, Zhang Shu, Li Ning, Yang Jianwei, Fan Qingxia, Wang Xiuwen, Zeng Shan, Zhang Yingjun, Zhang Weihong, Zhuang Yulei, Kang Ning, Jiang Yingzhi, Sun Hongmei, Xu Jianming
Abstract excerpt
BACKGROUND: Larotinib is a new first-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. This open-label, phase 1b study is aimed to evaluate the efficacy, safety of larotinib in patients with advanced esophageal squamous cell carcinoma (ESCC) with EGFR overexpression or amplification pretreated with one or more system regimens, and to recommend an appropriate dose for its further study....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.